#China #Shenzhen #Clinical Trial #Kexing Biopharm #GB10

Kexing Biopharm's Groundbreaking Clinical Trial for GB10

On June 5, 2026, Kexing Biopharm made headlines as it announced the enrollment and treatment of the first participant in the Phase I clinical trial for GB10 Injection, an innovative ophthalmic drug. This drug is independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm. GB10 targets neovascular age-related macular degeneration (nAMD), a leading cause of blindness worldwide in individuals over 50 years old.

The GB10 formulation is a highly concentrated ophthalmic protein drug containing a bispecific antibody targeting both VEGF and Ang-2, critical components in neovascularization. One of the standout features of GB10 is its 140 mg/ml concentration, which either allows for a smaller injection volume or higher dosage. This innovation is expected to extend the dosing intervals significantly, potentially allowing a regimen of once every four months, thus improving patient adherence substantially.

Preclinical studies have demonstrated GB10's competitive ability on an international scale. In models of laser-induced choroidal neovascularization (CNV), the drug has shown efficacy in inhibiting pathological neovascularization in the retina, which is critical for addressing nAMD.

As the global demand for ophthalmic treatments continues to rise, driven by factors such as increased screen time and an aging population, the clinical challenges of frequent injections and poor patient adherence become more pressing. GB10's prolonged dosing interval aims to alleviate these concerns, representing a significant advancement in treatment options for nAMD.

In addition to GB10, Kexing Biopharm is advancing its research and development pipeline for dual-action ophthalmic antibodies and plans to actively introduce externally developed ophthalmic products into international markets. These include biosimilars of aflibercept and olopatadine hydrochloride eye drops. Such efforts are aimed at expanding Kexing's global presence and enhancing its internationalization through continuous innovation.

Kexing is steadfast in its mission of providing "Accurate products, predictable results, and health protection". The company aims to deliver high-quality, accessible treatment options worldwide, affirming its commitment to improving patient care through innovative solutions.

The successful initiation of this clinical trial signifies a major milestone not just for Kexing Biopharm, but also for the development of ophthalmology-related pharmaceuticals, which stands to benefit many patients in dire need of effective therapies.